Techniques for Various Routes of Drug Administration

Introduction/Overview

The selection and proper execution of a drug administration route constitute a fundamental clinical skill, directly influencing therapeutic efficacy, safety, and patient adherence. The route of administration determines the onset, intensity, and duration of a drug’s pharmacological action by governing its absorption, distribution, and bioavailability. Mastery of these techniques is therefore not merely procedural but integral to rational pharmacotherapy. Errors in administration can lead to treatment failure, adverse events, or patient harm, underscoring the critical importance of this knowledge for all healthcare practitioners involved in medication management.

The clinical relevance extends across all medical disciplines, from emergency medicine, where rapid intravenous access can be lifesaving, to chronic disease management, where patient-friendly oral or subcutaneous routes promote long-term adherence. Each route presents a unique set of advantages, limitations, and technical requirements that must be matched to the drug’s physicochemical properties, the desired therapeutic outcome, and the patient’s individual condition.

Learning Objectives

• Compare and contrast the anatomical, physiological, and pharmacokinetic principles underlying the oral, intravenous, intramuscular, subcutaneous, and intraperitoneal routes of administration.
• Describe the standard techniques, required equipment, and appropriate anatomical sites for each route, with emphasis on aseptic practice and patient safety.
• Analyze the factors influencing drug absorption and bioavailability for each route, including formulation effects and pathophysiological variables.
• Identify the primary clinical indications, advantages, and disadvantages associated with each administration method.
• Recognize common and serious complications specific to each route and outline strategies for their prevention and management.

Classification of Administration Routes

Drug administration routes are systematically classified based on the site of application relative to the body. The primary categorization distinguishes between enteral and parenteral routes. Enteral administration involves the alimentary canal, while parenteral administration bypasses the gastrointestinal tract, typically involving injection through the skin or mucous membranes. A further distinction can be made based on whether the drug action is intended to be local or systemic.

Major Categories

• Enteral Routes: Administration directly into the gastrointestinal tract. The oral route is the most common, but enteral also includes sublingual, buccal, and rectal administration. These routes are subject to first-pass metabolism (excluding sublingual/buccal and rectal for some drugs).
• Parenteral Routes: Administration outside the alimentary canal, requiring a break in the skin or mucous membrane. This category includes intravenous (IV), intramuscular (IM), subcutaneous (SC), intraperitoneal (IP), intradermal, intra-arterial, intrathecal, and epidural routes. Sterility is paramount.
• Other Routes: Topical (skin), transdermal, inhalation, nasal, ophthalmic, and otic routes. These are often used for local effect but can achieve systemic delivery under certain conditions (e.g., transdermal patches, inhaled corticosteroids).

This chapter will focus on the core techniques for oral, intravenous, intramuscular, subcutaneous, and intraperitoneal administration, as these represent the most frequently employed methods for systemic drug delivery in clinical practice.

Mechanism of Action: Principles of Drug Delivery and Absorption

The mechanism by which a drug reaches the systemic circulation and its site of action is fundamentally governed by the chosen route. This involves a series of physical and biological barriers that the drug must traverse.

General Principles of Absorption

For a drug to exert a systemic effect, it must be absorbed into the bloodstream. Absorption is the movement of an unchanged drug from its site of administration into the systemic circulation. The rate and extent of absorption depend on multiple factors: the drug’s molecular size, lipid solubility, degree of ionization (governed by its pK_a and the local pH), concentration gradient, surface area of the absorptive site, and local blood flow. Routes that deliver a drug directly into the blood (e.g., intravenous) circumvent the absorption phase entirely, resulting in 100% bioavailability and immediate onset.

Route-Specific Barriers and Pathways

Oral (Enteral): Drugs must dissolve in gastrointestinal fluids, survive the acidic environment of the stomach, resist enzymatic degradation, and cross the intestinal epithelium, primarily via passive diffusion or active transport. They then enter the hepatic portal circulation and are subject to pre-systemic (first-pass) metabolism in the liver and gut wall before reaching the systemic circulation.

Parenteral Injections: These routes bypass the gastrointestinal epithelium. Absorption into capillaries occurs from the interstitial space at the injection site (IM, SC) or from the peritoneal cavity (IP). The rate is determined by the vascularity of the tissue, the drug’s solubility, and the formulation (e.g., aqueous solution vs. depot suspension). Intravenous administration provides direct intravascular access.

Pharmacokinetics by Route of Administration

The route of administration is the primary determinant of a drug’s pharmacokinetic profile—its absorption, distribution, metabolism, and excretion (ADME). The following analysis highlights the key pharmacokinetic differences.

Absorption

Absorption characteristics vary profoundly. Intravenous administration offers instantaneous and complete absorption (bioavailability, F = 1). In contrast, oral absorption is often delayed, incomplete, and variable due to factors like gastric emptying, food interactions, and first-pass effect (F ≤ 1). Intramuscular and subcutaneous routes provide absorption rates that are intermediate between IV and oral, influenced by local blood flow and formulation.

Distribution, Metabolism, and Excretion

While distribution, metabolism, and excretion are primarily drug-specific properties, the route can influence their initial phases. For instance, a drug administered intravenously achieves a high initial concentration (C_max) in the central compartment (blood) immediately, which can affect its volume of distribution (V_d) calculations and potentially saturate metabolic or binding pathways. Orally administered drugs enter via the hepatic portal system, ensuring that the liver, a major site of metabolism, is exposed to the highest initial concentration, which may enhance first-pass extraction. The elimination half-life (t_1/2) is generally independent of the route, provided bioavailability is complete, as t_1/2 is a function of clearance (CL) and volume of distribution (t_1/2 = 0.693 × V_d / CL).

Therapeutic Uses and Clinical Applications

The selection of an administration route is a therapeutic decision based on drug properties, desired onset/duration, and clinical context.

Oral Administration

Oral administration is the cornerstone of outpatient and chronic pharmacotherapy due to its convenience, cost-effectiveness, and generally good patient acceptance. It is suitable for a vast array of solid (tablets, capsules) and liquid formulations. It is the preferred route for maintenance therapy where rapid onset is not critical, such as in hypertension, diabetes mellitus (e.g., metformin), dyslipidemia, and chronic pain management. Enteric-coated or modified-release formulations are used to protect drugs from gastric acid or to provide sustained action.

Intravenous Administration

The IV route is indispensable in clinical scenarios requiring immediate and predictable therapeutic effects. Primary indications include:

• Emergency Medicine: Administration of resuscitative drugs (epinephrine, atropine), anticonvulsants (lorazepam), and analgesics (morphine).
• Critical Care: Continuous infusion of vasoactive drugs (norepinephrine), sedatives (propofol), and inotropes.
• Hospital Settings: Delivery of drugs with poor oral bioavailability (e.g., many antibiotics like aminoglycosides, antifungals like amphotericin B), chemotherapeutic agents, and total parenteral nutrition.
• Diagnostic Procedures: Administration of contrast media for imaging studies.

Intramuscular Administration

IM injections are utilized when a drug cannot be given orally (due to instability, first-pass effect, or patient compliance issues) and a rapid but not instantaneous onset is acceptable, or when a depot formulation is desired. Common applications include:

• Vaccinations (e.g., influenza, hepatitis B).
• Administration of antipsychotics in long-acting depot formulations (e.g., haloperidol decanoate).
• Administration of analgesics (e.g., opioids like morphine), antiemetics (e.g., metoclopramide), and hormones (e.g., medroxyprogesterone acetate for contraception).
• Emergency administration of drugs when IV access is unavailable (e.g., epinephrine for anaphylaxis via auto-injector).

Subcutaneous Administration

The SC route is ideal for drugs that require slow, sustained absorption and for patient self-administration. Key uses include:

• Diabetes management: Insulin and glucagon-like peptide-1 (GLP-1) receptor agonists.
• Anticoagulation: Low-molecular-weight heparins (e.g., enoxaparin).
• Biologic therapies: Monoclonal antibodies (e.g., adalimumab), erythropoiesis-stimulating agents.
• Palliative care: Continuous infusion of analgesics via SC syringe drivers.
• Allergy immunotherapy: Gradual desensitization with allergen extracts.

Intraperitoneal Administration

Intraperitoneal administration has more limited and specialized clinical applications, primarily because it is an invasive procedure with specific risks. Its main uses are:

• Peritoneal Dialysis: The dialysis fluid, containing electrolytes and glucose, is instilled into the peritoneal cavity to facilitate solute exchange and ultrafiltration in patients with end-stage renal disease.
• Intraperitoneal Chemotherapy: Used in the management of certain ovarian and gastrointestinal malignancies. Delivering chemotherapeutic agents (e.g., cisplatin) directly into the peritoneal cavity achieves high local concentrations to treat peritoneal carcinomatosis while potentially reducing systemic toxicity.
• Animal Research: A common route for drug administration in laboratory rodents due to the relative ease of access and large absorptive surface area.

Adverse Effects and Complications

Each route carries a distinct profile of potential adverse effects and procedural complications, ranging from minor local reactions to life-threatening systemic events.

Oral Administration

Adverse effects are primarily related to the drug’s systemic pharmacology. Local gastrointestinal effects are common and include nausea, vomiting, epigastric distress, diarrhea, and constipation. These can often be mitigated by taking medication with food, though food may impair absorption of some drugs. More serious complications include direct mucosal injury (e.g., ulceration from NSAIDs or bisphosphonates) and pill esophagitis if the tablet becomes lodged. Systemic toxicity from overdose is a constant concern due to the ease of administration and patient error.

Intravenous Administration

Complications are frequent and can be severe, necessitating vigilant monitoring.

• Local Complications: Phlebitis (inflammation of the vein), infiltration (leakage of non-vesicant fluid into surrounding tissue), extravasation (leakage of vesicant or irritant drugs causing tissue necrosis), thrombosis, and infection at the insertion site.
• Systemic Complications: Immediate and severe anaphylactic or anaphylactoid reactions. Pyrogenic reactions from microbial contaminants. Fluid overload, electrolyte imbalances, and osmotic disturbances. Air or particulate embolism from improper technique. The rapid onset also means that dosing errors can have immediate catastrophic consequences.

Intramuscular Administration

Complications are often local but can have significant functional consequences.

• Pain, bleeding, and bruising at the injection site.
• Formation of sterile abscesses or granulomas, particularly with oil-based depot formulations.
• Nerve injury, which can be permanent, if the injection inadvertently hits a major nerve trunk (e.g., sciatic nerve injury from gluteal injection).
• Muscle fibrosis and contracture with repeated injections.
• Intravascular injection, potentially leading to rapid systemic effects or embolism if the drug is formulated in an oil base.

Subcutaneous Administration

Adverse effects are typically localized and mild but can affect treatment adherence.

• Pain, erythema, itching, and swelling at the injection site.
• Lipohypertrophy (lumpy swelling due to fat cell growth) or lipoatrophy (loss of subcutaneous fat), commonly seen with repeated insulin injections at the same site. This can impair drug absorption.
• Localized infection or sterile abscess formation.
• Hematoma formation, particularly with anticoagulant administration.

Intraperitoneal Administration

This invasive procedure carries significant risks.

• Infection: Peritonitis is a serious and common complication, particularly in peritoneal dialysis patients.
• Visceral Injury: Puncture of the bowel, bladder, or major blood vessels during catheter insertion or drug administration.
• Pain and Discomfort: During fluid instillation or from chemical irritation by the administered drug (e.g., abdominal pain with intraperitoneal chemotherapy).
• Adhesions: Fibrous bands can form within the peritoneal cavity following inflammation or infection, which may complicate future procedures or dialysis efficacy.
• Metabolic Complications: In peritoneal dialysis, absorption of glucose from the dialysate can lead to hyperglycemia and weight gain.

Drug Interactions and Contraindications

While most clinically significant drug interactions are pharmacodynamic or pharmacokinetic in nature (e.g., enzyme induction/inhibition, receptor antagonism), the route of administration can influence the risk or severity of certain interactions.

Route-Specific Interaction Considerations

Oral Route: Most susceptible to interactions that alter gastrointestinal physiology. Antacids, proton pump inhibitors, and H₂ antagonists can increase gastric pH, affecting the dissolution and absorption of drugs that require an acidic environment (e.g., ketoconazole, atazanavir). Drugs that alter gastric motility (e.g., metoclopramide accelerates, opioids delay) can change absorption rates. Chelation complexes can form between drugs (e.g., tetracyclines and divalent cations like Ca²⁺ in dairy).

Parenteral Routes: Physical and chemical incompatibilities are a major concern, especially for IV administration. Mixing drugs in the same syringe or IV bag can lead to precipitation, inactivation, or formation of toxic compounds. For example, heparin is incompatible with many antibiotics. The IV administration of a drug that is highly protein-bound (e.g., warfarin) can be displaced by another highly bound drug administered concurrently, leading to a transient increase in free, active drug concentration.

General Contraindications

• Oral: Contraindicated in patients with severe nausea/vomiting, intestinal obstruction, malabsorption syndromes, or impaired consciousness/uncooperative state posing an aspiration risk. Also contraindicated for drugs destroyed by gastric acid or undergoing extensive first-pass metabolism if an alternative exists.
• Intravenous: Relative contraindications include severe coagulopathy or thrombocytopenia, which increase bleeding risk from venipuncture. It is contraindicated for drugs formulated for other routes only (e.g., depot suspensions).
• Intramuscular: Contraindicated in patients with severe thrombocytopenia or coagulopathy due to risk of hematoma. Should be avoided in shock states with poor muscle perfusion, as absorption will be erratic. Not suitable for irritant drugs that cause tissue necrosis.
• Subcutaneous: Generally contraindicated for administration of large volumes (>2 mL in adults) or highly irritant substances, as these can cause severe pain and tissue damage.
• Intraperitoneal: Absolute contraindications include peritonitis, severe abdominal adhesions, and recent abdominal surgery. It is contraindicated for non-sterile drugs or in the presence of an uncorrectable bleeding diathesis.

Special Considerations

Patient-specific factors necessitate careful consideration when selecting and executing a drug administration route.

Use in Pregnancy and Lactation

The route itself does not inherently alter the teratogenic or fetotoxic potential of a drug, but it can influence maternal pharmacokinetics and thus fetal exposure. For example, the increased cardiac output and altered plasma protein binding in pregnancy may affect drug distribution. During labor, IM or IV routes are standard for administering analgesics, oxytocics, or antibiotics. For lactating women, the oral bioavailability of a drug in the mother has little bearing on its excretion into breast milk, which depends on other pharmacokinetic parameters. However, topical or inhaled routes may theoretically minimize systemic maternal exposure and thus transfer to milk.

Pediatric Considerations

Anatomical and physiological differences are critical. In neonates and infants, IM injections should be given with caution due to small muscle mass; the vastus lateralis (thigh) muscle is preferred over the gluteal region to avoid sciatic nerve injury. SC injections may be less reliable due to reduced subcutaneous tissue. Oral administration of liquid formulations is common, but taste and volume are significant adherence factors. IV access can be challenging, and fluid volumes must be meticulously calculated to avoid overload. The intraperitoneal route is rarely used in pediatric patients outside of specialized dialysis or oncology protocols.

Geriatric Considerations

Age-related changes impact all routes. Reduced muscle mass and peripheral perfusion can delay and variably affect absorption from IM and SC sites, making IV or oral routes more predictable. Skin fragility increases the risk of bruising and tearing from injections. Impaired renal and hepatic function alters drug elimination, which is particularly dangerous for drugs given IV where onset is immediate. Cognitive impairment may affect the ability to self-administer oral or SC medications correctly, necessitating caregiver support or alternative routes.

Renal and Hepatic Impairment

While these conditions primarily affect drug metabolism and excretion (pharmacokinetics), the route of administration can influence management strategies. In severe hepatic impairment with portosystemic shunting, the first-pass effect for oral drugs is diminished, potentially leading to increased and unpredictable bioavailability; this may necessitate dose reduction or a switch to a parenteral route where dosing is more directly controllable. In renal impairment requiring dialysis, the route must be timed relative to dialysis sessions. Drugs administered intravenously immediately before hemodialysis may be largely removed, reducing efficacy. In such cases, post-dialysis dosing or the use of routes with slower absorption (SC, IM) may be considered to maintain therapeutic levels. Peritoneal dialysis, of course, utilizes the intraperitoneal route directly.

Summary and Key Points

The selection and proficient execution of a drug administration route are foundational to safe and effective medical practice. Each route presents a unique profile of pharmacokinetic characteristics, clinical utilities, and inherent risks.

Clinical Pearls

• The oral route, while convenient and economical, is subject to significant pharmacokinetic variability due to first-pass metabolism and gastrointestinal factors; it is unsuitable for emergencies or for drugs with very low oral bioavailability.
• Intravenous administration provides immediate and complete drug delivery but carries the highest risk of severe immediate complications, including anaphylaxis, extravasation, and infection; it requires the highest level of monitoring and technical skill.
• Intramuscular injections offer a reliable method for achieving rapid systemic effects when IV access is not available or for administering depot formulations; careful attention to anatomical landmarks is essential to avoid nerve injury.
• Subcutaneous injection is the route of choice for many chronic self-administered therapies like insulin and heparin; site rotation is critical to prevent lipodystrophy and ensure consistent absorption.
• Intraperitoneal administration is a specialized technique reserved primarily for peritoneal dialysis and intraperitoneal chemotherapy, associated with significant risks like peritonitis and visceral injury; it should only be performed by trained clinicians in appropriate settings.
• Sterile technique is non-negotiable for all parenteral routes. The “five rights” of medication administration (right patient, drug, dose, route, time) must be rigorously verified before any drug is given.
• Patient-specific factors—including age, comorbid conditions (coagulopathy, shock), and anatomical considerations—must always inform the choice of route and technique.

Ultimately, the optimal route balances the drug’s physicochemical properties, the desired speed and duration of action, the clinical context, and patient safety and comfort. A deep understanding of these principles enables clinicians to tailor drug delivery to maximize therapeutic benefit while minimizing harm.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.